# Vyvgart (efgartigimod alfa) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efgartigimod-alfa

> The FDA approved Vyvgart (efgartigimod alfa), sponsored by ARGENX SE (ARGX), on April 10, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vyvgart (efgartigimod alfa) |
| Codes |  |
| Sponsor | ARGENX SE (ARGX) https://sec-api.dev/companies/argx/catalysts |
| Indications | [autoimmune myositis](https://sec-api.dev/indications/autoimmune-myositis), ocular myasthenia gravis |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### December 17, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761195 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22

### Jul 2023: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001697862-25-000020): "In July 2023, we announced positive topline results from the ADHERE clinical trial evaluating VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm
- SEC Form 10-K (accession 0001697862-25-000024): "In July 2023, we announced positive topline results from the ADHERE clinical trial evaluating VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) in adults with CIDP." https://www.sec.gov/Archives/edgar/data/1697862/000169786225000024/argx-20241231.htm

### August 8, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761195 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240808, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22

### April 10, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-04-11, last confirmed 2025-04-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-033857): "Exhibit 99.1 argenx Announces FDA Approval of" https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm

### October 17, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761195 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22

### February 26, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: ocular myasthenia gravis.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-020017): "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG)." https://www.sec.gov/Archives/edgar/data/1697862/000110465926020017/tm267379d1_ex99-1.htm

### May 8, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-05-11, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761195 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058143): "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for VYVGART® (efgartigimod alfa-fcab) and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG)." https://www.sec.gov/Archives/edgar/data/1697862/000110465926058143/tm2614130d1_ex99-1.htm

### August 17, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: autoimmune myositis.
- First seen 2026-08-17, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-097589): "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)" https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-070517): "•Myositis: In August 2026, Zai Lab and partner argenx announced positive topline results from the Phase 3 ALKIVIA study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis." https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/zlab-2026115x8kex991.htm

## Same indication

- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efgartigimod-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vyvgart (efgartigimod alfa) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efgartigimod-alfa

```bibtex
@misc{secapidev_pdufa_efgartigimod_alfa_20261116,
  title        = {Vyvgart (efgartigimod alfa) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efgartigimod-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efgartigimod_alfa_20261116","title":"Vyvgart (efgartigimod alfa) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efgartigimod-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
